官方通报“南极磷虾油”事件：已成立联合调查组开展调查

Core Viewpoint - The article discusses the controversy surrounding "Antarctic krill oil" products linked to Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., which has led to regulatory investigations and significant brand management actions by the company [1][5][9]. Group 1: Regulatory Actions - The Chengdu New District Market Supervision Administration has established a joint investigation team to look into the "Antarctic krill oil" incident, with the case currently under investigation [1]. - The company has been ordered to stop the sale of the implicated products and is required to compensate consumers as per regulatory guidelines [5]. Group 2: Company Response - Beijing Tongrentang Group issued an apology for the damage caused to consumers and initiated a zero-tolerance brand management action, including a comprehensive investigation of the involved products [5]. - The company is pursuing legal action against the involved parties for trademark infringement and misleading consumers regarding the use of the "Beijing Tongrentang" name [9]. Group 3: Product Quality Concerns - A product marketed as "Beijing Tongrentang 99% High Purity Antarctic Krill Oil" was found to have a phospholipid content of 0, raising concerns about product authenticity [7]. - The product was not directly produced by Beijing Tongrentang but was distributed by its subsidiary, which has been criticized for its brand management and quality control practices [9]. Group 4: Brand Reputation - Beijing Tongrentang, a historic brand established in 1669, has faced multiple trust crises due to issues related to brand licensing and quality control of its subsidiary products [9].